Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Stevenson

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flowJames P Stevenson, Mark Rosen, Weijing Sun, et al.
JCO Precision Oncology|February 9, 2022
Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center ExperienceMeena Sadaps, Pauline Funchain, Haider Mahdi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical responseRamesh Rengan, Rosemarie Mick, Daniel Pryma, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Oncoimmunology|November 2, 2013
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsJames P Stevenson, Hedy L Kindler, Emmanouil Papasavvas, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.
Cancer|January 17, 2020
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapyJared M Weiss, Nathan Pennell, Allison M Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancerStephen M Hahn, Eric J Bernhard, William Regine, et al.
Journal of the National Cancer Institute|November 11, 2015
Prospective Clinical Study of Precision Oncology in Solid TumorsDavendra P S Sohal, Brian I Rini, Alok A Khorana, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2013
Impact of PET staging in limited-stage small-cell lung cancerEric P Xanthopoulos, Michael N Corradetti, Nandita Mitra, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flowJames P Stevenson, Mark Rosen, Weijing Sun, et al.
JCO Precision Oncology|February 9, 2022
Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center ExperienceMeena Sadaps, Pauline Funchain, Haider Mahdi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical responseRamesh Rengan, Rosemarie Mick, Daniel Pryma, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Oncoimmunology|November 2, 2013
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsJames P Stevenson, Hedy L Kindler, Emmanouil Papasavvas, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.
Cancer|January 17, 2020
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapyJared M Weiss, Nathan Pennell, Allison M Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancerStephen M Hahn, Eric J Bernhard, William Regine, et al.
Journal of the National Cancer Institute|November 11, 2015
Prospective Clinical Study of Precision Oncology in Solid TumorsDavendra P S Sohal, Brian I Rini, Alok A Khorana, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2013
Impact of PET staging in limited-stage small-cell lung cancerEric P Xanthopoulos, Michael N Corradetti, Nandita Mitra, et al.
Pageof 5